Sirtex: Result 2014

Sirtex had another bumper year of profit growth, with more to come as England expands patient access.

Just like most other companies, Sirtex Medical faces a daily struggle with competition, fighting to take its business away, but Sirtex's major competitor isn’t another business – it’s death. Liver cancer is the fifth most common cancer in the world and sadly has a five-year survival rate of just 15%.

The company’s main product is an internal radiotherapy for liver cancer known as SIR-Spheres. However, it’s currently only used as a last resort due to severe side effects – which means many patients die before they have the opportunity to use it.



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles